The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2.

MLA

Suryawanshi, Rahul K., et al. “The Mac1 ADP-Ribosylhydrolase Is a Therapeutic Target for SARS-CoV-2.” BioRxiv : The Preprint Server for Biology, Aug. 2024. EBSCOhost, https://doi.org/10.1101/2024.08.08.606661.

APA

Suryawanshi, R. K., Jaishankar, P., Correy, G. J., Rachman, M. M., O’Leary, P. C., Taha, T. Y., Zapatero-Belinchón, F. J., McCavittMalvido, M., Doruk, Y. U., Stevens, M. G. V., Diolaiti, M. E., Jogalekar, M. P., Richards, A. L., Montano, M., Rosecrans, J., Matthay, M., Togo, T., Gonciarz, R. L., Gopalkrishnan, S., … Fraser, J. S. (2024). The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2. BioRxiv : The Preprint Server for Biology. https://doi.org/10.1101/2024.08.08.606661

Chicago

Suryawanshi, Rahul K, Priyadarshini Jaishankar, Galen J Correy, Moira M Rachman, Patrick C O’Leary, Taha Y Taha, Francisco J Zapatero-Belinchón, et al. 2024. “The Mac1 ADP-Ribosylhydrolase Is a Therapeutic Target for SARS-CoV-2.” BioRxiv : The Preprint Server for Biology, August. doi:10.1101/2024.08.08.606661.